Monte Rosa Therapeutics (GLUE) EPS (Weighted Average and Diluted): 2023-2025
Historic EPS (Weighted Average and Diluted) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$0.33.
- Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) fell 13.79% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 117.58%. This contributed to the annual value of -$0.98 for FY2024, which is 62.74% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) is -$0.33, which was down 120.00% from -$0.15 recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.57 in Q1 2025 and a low of -$0.71 during Q2 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.32, with a median of -$0.43 in 2024.
- Data for Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY increase of 207.55% (in 2025) and a maximum YoY decrease of 13.79% (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.57 in 2023, then skyrocketed by 140.35% to $0.23 in 2024, then dropped by 13.79% to -$0.33 in 2025.
- Its last three reported values are -$0.33 in Q3 2025, -$0.15 for Q2 2025, and $0.57 during Q1 2025.